Skip to main
EW
EW logo

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 32%
Hold 26%
Sell 5%
Strong Sell 0%

Bulls say

Edwards Lifesciences has demonstrated robust growth in its transcatheter aortic valve replacement (TAVR) segment, achieving a 10.6% increase in sales during the latest quarter, marking the strongest growth performance since late 2023. The company's expectations for fiscal year 2025 have been revised upwards, with anticipated revenue growth now projected at the high end of the 9-10% range and earnings per share (EPS) expected to rise to $2.56-$2.62, indicating strong financial momentum and confidence in continued growth. Key drivers of this outlook include significant growth in tricuspid and mitral valve procedures, along with a strong focus on aortic stenosis treatment among physicians, further supporting accelerated TAVR growth forecasts for the upcoming year.

Bears say

The financial outlook for Edwards Lifesciences appears negative due to several key factors that could hinder future growth. The anticipated expansion of the transcatheter aortic valve replacement (TAVR) market may not meet investor expectations, with potential challenges including slower adoption rates of upcoming technology and increased competition that could impact market share and pricing. Additionally, delays in the innovation pipeline for tricuspid and mitral valve repair products pose risks to the company's sales growth, as substantiated clinical data is necessary for wider acceptance and successful product launches.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 32% recommend Buy, 26% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.